Tagrisso is already approved in more than 100 countries, including the U.S. “At least in this one area, we’ve hit the mark,” Herbst said. Last year, the Biden administration set a moonshot goal of reducing the cancer death rate in the U.S. The researchers found that the drug lowered the overall risk of death from lung cancer by 51%. The study was funded by AstraZeneca and included people from more than 20 countries across the U.S., Europe, South America, Asia and the Middle East. Five years after their diagnosis, 88% of those who took the pill were still alive, compared with 78% of the placebo group. ![]() In an international study of 682 lung cancer patients, roughly half of the participants were given the daily pill for three years, while the other half received a placebo. ![]() ![]() The trial results were “about twice as good as we expected,” Herbst added.
0 Comments
Leave a Reply. |